AMRA Medical’s Muscle Composition Analysis Used to Evaluate the Effect of Liraglutide Treatment in Obesity
2024年5月2日 - 10:35PM
ビジネスワイヤ(英語)
Results from a randomized, double-blind trial in diabetes-free
adults living with obesity and high cardiovascular disease risk
showed that liraglutide was associated with a reduction in both
muscle fat infiltration and prevalence of adverse muscle
composition when compared to placebo
AMRA Medical - a health informatics and precision medicine
company that is pioneering body composition research through
gold-standard MRI-based analysis platforms - collaborated on a
study driven by University of Texas Southwestern and University
Hospital Cleveland to publish new data revealing the effect of
liraglutide treatment on muscle composition in adults with
obesity.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240502719692/en/
Credit: Collaboration with Dr. Ian J
Neeland, University Hospitals Cleveland. Data from NCT03038620
(ClinicalTrials.gov identifier) analysed with AMRA® Researcher
The analysis included 128 diabetes-free adults with obesity who
received a lifestyle intervention in addition to being randomized
to either a liraglutide (n = 73) or a placebo (n = 55) treatment
group. Using the proprietary MRI-based AMRAⓇ Researcher, baseline
and follow-up muscle composition analyses were performed, with the
primary objective of assessing change in thigh muscle fat
infiltration due to treatment intervention over a 40-week period.
Participants were also assessed for the exploratory outcome of
adverse muscle composition, defined as high muscle fat infiltration
and low muscle volume z-score.
Among the 128 participants, median muscle fat infiltration at
baseline was 7.8%. The study found that liraglutide significantly
reduced muscle fat infiltration when compared to placebo. The mean
percent change in muscle fat infiltration for those randomized to
liraglutide was -2.87% from baseline, and 0.05% in the placebo arm
(absolute change: -0.23% vs. 0.01%). Additionally, a
weight-invariant assessment of muscle volume was performed using
AMRA’s muscle volume z-score did not show a significant reduction
comparing liraglutide to placebo (mean treatment difference
adjusted for baseline muscle volume z-score was -0.08 standard
deviations). The study also uncovered that the proportion of
participants with adverse muscle composition dropped from 11.0% to
8.2% over follow-up in the liraglutide arm, while no change in the
placebo arm was observed.
While the contribution of muscle fat infiltration improvement to
the cardiometabolic benefits of liraglutide requires further
investigation, the above findings come at a critical time given the
global rise of obesity incidence and its comorbidities posing more
of a threat to patients than ever before. As the treatment paradigm
begins to shift from solely lifestyle changes to one that includes
pharmacological intervention (namely the popular GLP-1 agonists
such as liraglutide) and drug development in obesity ramps up, it
is paramount that these drugs are accurately assessed for their
impact on muscle composition to ensure that the weight loss they
help to achieve does not result in adverse effects on muscle
health.
Through their gold-standard MRI-based body composition analysis
technology, AMRA is committed to pioneering the creation of
normative datasets explaining the effect of GLP-1s and
incretin-based treatments on muscle composition to help the obesity
field gain further insight as to how these drugs work in this
relatively new indication. Recently, AMRA presented related
findings at the 59th European Association for the Study of Diabetes
Annual Meeting, where it was shown that another popular GLP-1,
tirzepatide, achieved significant weight loss without any adverse
effects on muscle composition. You can view the presentation
here.
Learn more about AMRA Medical and how the use of MRI-based body
composition analysis is advancing disease research in metabolic
diseases including obesity, and beyond.
About AMRA Medical
AMRA Medical is a health informatics and precision medicine
company that is pioneering body composition analysis, providing
cutting-edge solutions to advance both clinical research and
patient care initiatives. AMRA's gold-standard technology delivers
multiple fat and muscle biomarkers - derived simply from rapid
whole-body MRI scans. AMRA is committed to driving transformative
care and simplifying vital decision-making in both research and
clinical care settings by offering support services via their
innovative platform.
Learn more about AMRA Medical’s MRI-based solutions at
https://amramedical.com/solutions, or connect with our team of
experts for a detailed discussion at info@amramedical.com.
Follow AMRA on LinkedIn for the latest updates in body
composition and precision medicine.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240502719692/en/
AMRA Medical Marie B�rjesson, VP Brand & Marketing 0046 70
628 1977 marie.borjesson@amramedical.com